Commission activities in the area of Tuberculosis


Approximately 1.5 million people die each year as a result of tuberculosis (TB) and up to 2 billion people are infected with the causative agent, Mycobacterium tuberculosis. These numbers demonstrate that M. tuberculosis is one of the most successful pathogens ever encountered. In the 7th Framework Programme the EU has invested a total of € 118 million in 50 TB projects. The investment in TB research was broadly divided into three areas: vaccines, drugs and diagnostics. A strong portfolio of TB research projects has been established in all of these areas, ranging from small discovery projects to large multidisciplinary consortia with sufficient critical mass to undertake translational and clinical research. Research in this area continues under Horizon 2020. With funds from the Societal Challenge: Health, Demographic Change and Wellbeing, two TB vaccine projects started in 2015 with an EU investment of € 26.2 million. During the two first years, total Horizon 2020 investment in TB research has been € 58 million.

EU contribution to TB research in Horizon2020


TB is a disease with a delicate balance between the host and the pathogen

Due to the special nature of the disease, attention has been given to topics such as:

  1. The mechanisms of pathogenesis and disease in TB, and the interaction between M. tuberculosis and the human host
  2. Emergence of multidrug-resistance (MDR-TB) and extensive drug-resistance (XDR-TB)
  3. Co-infection and co-morbidity in TB


New drugs against TB

The EU funds projects that aim to develop new drugs against TB, especially because of the alarming increase of multidrug-resistance (MDR-TB). SMEs as well as large pharmaceutical companies play an important role in such projects so as to enable any new drug candidates to enter clinical trials and eventually reach the market.


Point of care diagnostic tests

In order to be able to control TB efficiently, infection with M. tuberculosis and the drug susceptibility profile of the identified strains needs to be rapidly and accurately determined before choosing the appropriate treatment regimen. The EU supports projects aimed at developing rapid diagnostic tests for use in clinical practice. Inexpensive and easy to use tests that can also be implemented in resource-poor settings are a priority.



No new vaccines have been introduced to prevent TB for 80 years. Development of new improved vaccines for TB is a complicated and time consuming endeavour. The EU has invested heavily in projects developing novel vaccines. The most promising candidates are already in the clinical phase of development.


International cooperation is the key to success

TB is a global problem and the responsibility to support research activities should be shared. The EU has built partnerships between its Member States and global players of the TB research field, and Horizon 2020 and 7th Framework Programme activities have contributed to integrating European efforts with the global TB research agenda. Fostering the transfer of drug and vaccine candidates to human clinical trials, and liaising with the European and Developing Countries Clinical Trials Partnership will enable further large clinical trials to be undertaken in developing countries.


Here are two TB success stories...with a link to more below

Image of dead tiger mosquito

A big booster for vaccine development

An EU-funded project has accelerated the development of vaccines for diseases such as Lyme disease, malaria, tuberculosis, dengue, influenza, mumps, whooping cough, pneumonia, HIV, and two types of cancer. Their work could lead to new, more effective vaccines - potentially saving millions of people from disease.

Current treatments are failing people with recurrent TB © Shutterstock

New strategy needed to stop tuberculosis reoccurring in poorer patients

The standard approach to re-treating tuberculosis (TB) in low and middle income settings is failing, according to new research. In a study published in the journal PLoS Medicine, scientists call for improved access to rapid diagnostics for drug-resistant TB, second—line TB treatment and antiretroviral HIV (human immunodeficiency virus) therapy. They point out that each year, between 1 in 10 and 1 in 5 patients treated for TB see their disease return after failing, interrupting or relapsing from treatment.

Read more tuberculosis research success stories